{"id":"NCT02504216","sponsor":"Bayer","briefTitle":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","officialTitle":"An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-18","primaryCompletion":"2019-11-27","completion":"2020-01-09","firstPosted":"2015-07-21","resultsPosted":"2020-12-08","lastUpdate":"2020-12-08"},"enrollment":6564,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Peripheral Artery Disease"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Rivaroxaban-Placebo","otherNames":[]}],"arms":[{"label":"Rivaroxaban","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.","primaryOutcome":{"measure":"Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology","timeFrame":"For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.","effectByArm":[{"arm":"Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od","deltaMin":508,"sd":null},{"arm":"Rivaroxaban Placebo Bid + Aspirin 100 mg od","deltaMin":584,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0043"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":532,"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Estonia","Finland","France","Germany","Hungary","Italy","Japan","Latvia","Lithuania","Netherlands","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["38493348","38377256","36470531","35699170","35467452","34711335","34380322","34010631","33138628","32222135","29754671"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":948,"n":3256},"commonTop":["Pain in extremity","Hypertension","Intermittent claudication","Atrial fibrillation","Peripheral arterial occlusive disease"]}}